Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Inozyme Pharma Inc (NASDAQ: INZY) closed at $1.24 in the last session, down -0.80% from day before closing price of $1.25. In other words, the price has decreased by -$0.80 from its previous closing price. On the day, 0.87 million shares were traded.
Ratios:
We take a closer look at INZY’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.68 and its Current Ratio is at 7.68. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.51.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on December 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $26.
On September 12, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $16.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 02 ’24 when Treco Douglas A sold 7,523 shares for $6.94 per share. The transaction valued at 52,210 led to the insider holds 20,665 shares of the business.
Stock Price History:
Over the past 52 weeks, INZY has reached a high of $7.80, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is -38.41%, while the 200-Day Moving Average is calculated to be -69.14%.
Shares Statistics:
A total of 64.18M shares are outstanding, with a floating share count of 43.56M. Insiders hold about 32.20% of the company’s shares, while institutions hold 59.15% stake in the company.
